Physicians' Academy for Cardiovascular Education

Impact of new diabetes drugs on cardiovascular outcomes

3' education - Apr. 18, 2014 - VBWG - ACC 2014 - Deepak L. Bhatt

The cardiovascular (CV) safety of diabetes treatments has long been questioned by the medical community, in particular the effect of new drugs on the risk for CV mortality, MI and stroke. Now, two new trials addressed the CV safety of dipeptidyl-peptidase IV inhibitors. 
Dr. Deepak Bhatt, Boston reviews multiple trials evaluating cardiovascular safety of new diabetes drugs such as the recently completed studies with DPP4 inhibitors (EXAMINE & SAVOR-TIMI53 studies) and ongoig trials with GLP1 agonists.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: